✦ LIBER ✦

PCN12 IMPACT OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS (CEA) OF A DOCETAXEL, DOXORUBICIN AND CYCLOPHOSPHAMIDE REGIMEN (TAC) VERSUS 5-FLUOROURACIL, DOXORUBICIN AND CYCLOPHOSPHAMIDE (FAC) IN FRANCE

✍ Scribed by H Miadi-Fargier; C Le Pen; MC Woronoff-Lemsi; JP Guastalla; X Pivot; H Roché; F Pinguet; B Favier; J Gligorov; I Debrix; M Spielmann; EC Antoine; M Cadilhac; GA De Pouvourville

Book ID: 118607520
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 81 KB
Volume: 8
Category: Article
ISSN: 1098-3015
DOI: 10.1016/s1098-3015(10)67250-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost–effectiveness analysis of adjuvant

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ Sang Gyu Lee; Young Geon Jee; Hyun Chul Chung; Sung-Bae Kim; Jungsil Ro; Young-H 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 231 KB

P180 A cost effectiveness analysis of ad

P180 A cost effectiveness analysis of adjuvant chemotherapy for node positive early breast cancer in South Africa: docetaxel, doxorubicin and cyclophosphamide (TAC) versus 5-fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ B.L. Rapoport; S.D. Moodley; C. Jacobs; R. Pienaar; S. Fourie; W.M. Szpak 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Quality of life and toxicity in breast c

Quality of life and toxicity in breast cancer patients using adjuvant TAC (docetaxel, doxorubicin, cyclophosphamide), in comparison with FAC (doxorubicin, cyclophosphamide, 5-fluorouracil)

✍ N. Hatam; N. Ahmadloo; A. Ahmad Kia Daliri; P. Bastani; M. Askarian 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 178 KB

Prospective randomized trial of 5-fluoro

Prospective randomized trial of 5-fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus paclitaxel and FAC (TFAC) in patients with operable breast cancer: impact of taxane chemotherapy on locoregional control

✍ Jeffrey M. Albert; Aman U. Buzdar; Reina Guzman; Pamela K. Allen; Eric A. Strom; 📂 Article 📅 2011 🏛 Springer US 🌐 English ⚖ 240 KB

PCN12 ECONOMIC EVALUATION OF ADJUVANT CH

PCN12 ECONOMIC EVALUATION OF ADJUVANT CHEMOTHERAPY WITH DOCETAXEL FOR EARLY BREAST CANCER: COST-EFFECTIVENESS ANALYSIS OF FEC-D VS FEC, IN PUBLIC HEALTH CARE INSTITUTIONS IN MEXICO

✍ Erazo-Valle, A; Lazaro, J; Lemus, A; Robles, J 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views